Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHT101 in CD70-positive solid tumors
NCT06730659Phase 1Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Apr 2024
- Primary completion
- Apr 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CHT101 in solid tumor, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Safety and Tolerability at 2 years. Started Apr 2024; status: recruiting.
02
Drugs
CHT101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06730659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06730659.